Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study

Figures & data

Table 1 Baseline Patient Characteristics

	N	Percentage
Age	Mean ± SD	(67.5 ± 6.9)
Sex
Male	37	97.4%
Female	1	2.6%
Smoke history
Yes	29	76.3%
No	9	23.7%
ECOG PS
0	3	7.9%
1	16	42.1%
2	16	42.1%
3	3	7.9%
Stage
IIIA	1	2.6%
IIIB	7	18.4%
IIIC	7	18.4%
IV	23	60.5%
Number of prior regimens
0	4	10.5%
1	19	50.0%
≥2	15	39.5%

Table 2 Treatment Responses

Evaluation	N	%
CR	0	0
PR	6	16.7%
SD	22	61.1%
PD	8	22.2%

Figure 1 Waterfall plot for the progression-free survival (PFS) of the 36 patients enrolled in the study. *The columns above the horizontal axis represent the patients who achieved PD (blue), whereas the below represent the patients who achieved PR (red) and SD (yellow).

Figure 2 Kaplan–Meier graph for the progression-free survival (PFS) in patients with SqCC (n = 36).

Figure 3 Kaplan–Meier graph for the overall survival (OS) of patients in the study (n = 38).

Table 3 Possible Treatment-Related Adverse Events

	I–II	III	IV	Total
Non-hematological
Hypertension	10 (26.3%)	6 (15.8%)	0	16 (42.1%)
Proteinuria	7 (18.4%)	2 (5.3%)	0	9 (23.7%)
Hand-foot reaction	8 (21.1%)	0	0	8 (21.1%)
Oral mucositis	4 (10.5%)	0	0	4 (10.5%)
Fatigue	15 (39.5%)	4 (10.5%)	0	19 (50.0%)
Loss of appetite	7 (18.4%)	2 (5.3%)	0	9 (23.7%)
Hemoptysis	7 (18.4%)	0	0	7 (18.4%)
Heart dysfunction	0	1 (2.6%)	0	1 (2.6%)
Abnormal liver function	1 (2.6%)	0	0	1 (2.6%)
Hematological
Neutropenia	2 (5.3%)	0	0	2 (5.3%)
thrombocytopenia	1 (2.6%)	0	0	1 (2.6%)